Abstract
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial showed that, in patients who had experienced a stroke or transient ischemic attack, treatment with high-dose atorvastatin over a 5-year period significantly reduced the risk of a subsequent stroke. SPARCL also showed that the benefits of an intensive statin regimen in these patients extended beyond reduction of secondary stroke to include significant reductions in future major vascular events. SPARCL has established statin treatment as a key component of a multimodal vascular risk reduction strategy after an ischemic stroke or transient ischemic attack. It is recommended that the vast majority of patients with ischemic cerebrovascular events should be started on statin therapy, preferably before discharge from acute hospitalization for their index event, with the goal of achieving and maintaining consensus guideline cholesterol targets as soon and for as long as possible.
Key Points
-
Statins are therapeutic agents with proven atheroprotective benefits that are thought to be mediated primarily through the lowering of serum LDL cholesterol concentration
-
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study showed that daily high-dose statin treatment reduces the incidence of future stroke and cardiovascular events in patients with recent stroke or transient ischemic attack
-
In the SPARCL study, treatment with atorvastatin was associated with a relative increase in intracerebral hemorrhage, but the net vascular benefit from statin treatment far outweighs this risk
-
The benefits of statin initiation in the immediate aftermath of an acute ischemic stroke remain unclear, although discontinuation of these drugs in this setting seems to be associated with poor outcome
-
The American Stroke Association recommends that a statin should be initiated during hospitalization for first ischemic stroke of atherosclerotic origin
-
Statins should form part of a multimodal approach to vascular risk reduction after stroke, which should also include antithrombotics, normoglycemics when indicated, and antihypertensives
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Amarenco P et al. (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35: 2902–2909
Rosenson RS (2000) Biological basis for statin therapy in stroke prevention. Curr Opin Neurol 13: 57–62
Delanty N and Vaughan CJ (1997) Vascular effects of statins in stroke. Stroke 28: 2315–2320
Switzer JA and Hess DC (2006) Statins in stroke: prevention, protection and recovery. Expert Rev Neurother 6: 195–202
Coull BM (2004) Statin therapy after acute ischemic stroke in the heart protection study: is the role in recurrent stroke prevention now defined? Stroke 35: 2233–2234
Amarenco P et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549–559
Sanossian N and Ovbiagele B (2006) Multimodality stroke prevention. Neurologist 12: 14–31
Jones PH et al. (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 92: 152–160
Nissen SE et al. (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The asteroid trial. JAMA 295: 1556–1565
Ansell BJ et al. (2003) Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108: 2751–2756
Amarenco P and Tonkin AM (2004) Statins for stroke prevention: disappointment and hope. Circulation 109: III44–III49
Albert MA et al. (2001) Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64–70
Wagner AH et al. (2002) 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol 22: 1784–1789
Nakata S et al. (2007) Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-κB pathway. Arterioscler Thromb Vasc Biol 27: 92–98
Vaughan CJ and Delanty N (1999) Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30: 1969–1973
Corvol JC et al. (2003) Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 163: 669–676
Collins R et al. (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20, 536 people with cerebrovascular disease or other high-risk conditions. Lancet 363: 757–767
US FDA: Center for Drug Evaluation and Research. New and Generic Drug Approvals, 1998–2004 [http://www.Fda.Gov/cder/approval/index.Htm] (accessed 22 April 2004)
Ovbiagele B et al. (2005) Expanding indications for statins in cerebral ischemia: a quantitative study. Arch Neurol 62: 67–72
Amarenco P et al. (2007) Lipoprotein, blood pressure and stroke risk: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study [abstract]. Neurology 68: A208
Sanossian N et al. (2007) High-density lipoprotein cholesterol: an emerging target for stroke treatment. Stroke 38: 1104–1109
Sturgeon JD et al. (2007) Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke 38: 2718–2725
Ariesen MJ et al. (2003) Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 34: 2060–2065
Neaton JD et al. (1993) Risk factors for death from different types of stroke. Multiple risk factor intervention trial research group. Ann Epidemiol 3: 493–499
Goldstein LB et al. (2007) Secondary analysis of hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study [abstract]. Neurology 68: A183
Schwartz GG et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711–1718
Greisenegger S et al. (2004) Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 221: 5–10
Yoon S et al. (2004) Rising statin use and effect on ischemic stroke outcome. BMC Med 2: 4
Ovbiagele B et al. (2007) Statin enhancement of collateralization in acute stroke. Neurology 68: 2129–2131
Kennedy J et al. (2007) Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 6: 961–969
Elkind MS (2007) Neuroprotection with Statin Therapy for Acute Recovery Trial (Neu-START) [http://clinicaltrials.Gov/ct/show/nct00243880;jsessionid= 8ec423e9a6a24645249f79bc404a1822?Order=6] (accessed 20 August 2007)
Sanossian N et al. (2006) Achieving target cholesterol goals after stroke: is hospital initiation the key. Arch Neurol 63: 1081–1083
Endres M and Laufs U (2006) Discontinuation of statin treatment in stroke patients. Stroke 37: 2640–2643
Blanco M et al. (2007) Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 69: 904–910
McGowan MP et al. (2004) There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 110: 2333–2335
Waters DD et al. (2006) Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study. J Am Coll Cardiol 48: 1793–1799
Stroke Council, American Heart Association and American Stroke Association (2004) Statins after ischemic stroke and transient ischemic attack: an advisory statement from the Stroke Council, American Heart Association and American Stroke Association. Stroke 35: 1023
Grundy SM et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–239
Sever PS et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149–1158
Shepherd J et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623–1630
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288: 2998–3007
Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22
[No authors listed] (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339: 1349–1357
Sacks FM et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001–1009
[No authors listed] (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389
National Heart, Lung and Blood Institute Adult Treatment Panel III Cholesterol Guidelines [www.nhlbi.nih.gov/guidelines/cholesterol] (accessed 30 October 2007)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N Sanossian has received honoraria from Astra-Zeneca. B Ovbiagele declared no competing interests.
Rights and permissions
About this article
Cite this article
Sanossian, N., Ovbiagele, B. Drug Insight: translating evidence on statin therapy into clinical benefits. Nat Rev Neurol 4, 43–49 (2008). https://doi.org/10.1038/ncpneuro0705
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0705